MIRA
INFORM REPORT
|
Report Date : |
16.03.2007 |
IDENTIFICATION
DETAILS
|
Name : |
Biosensors
Europe SA |
|
|
|
|
Registered Office : |
Cardiologie, Rue de Lausanne 31, 1110 Morges/VD |
|
|
|
|
Country : |
Switzerland |
|
|
|
|
Date of Incorporation : |
09-03-2005 |
|
|
|
|
Legal Form : |
Joint stock
company |
|
|
|
|
Line of Business : |
Distribution
of medical devices used in interventional cardiology in Europe, as well as
the provision of financial and trading services. |
RATING &
COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
EUR 150.000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
detail assessment: |
payments: |
|
|
|
The financial
affairs are considered to be in order. |
|
|
|
Individual credit limit*: |
EUR 150.000.-- |
Name
Biosensors Europe SA
Line of Business
Distribution de materiels en
Legal domicile
cardiologie
Rue de Lausanne 31
1110 Morges/VD
Switzerland
Telephone :
021 8048000
Fax :
021 8048002
Homepage :
http://www.biosensors.com
E-Mail :
europe@biosensors.com
CREDIT ADVICE
Credit opinion: A maximum credit of EUR 150.000 is considered in order.
This credit advice is based on information
available at the time of conducting the research, being the above indicated
date.
All amounts in this report are given in
Swiss Francs (CHF) unless otherwise stated.
GENERAL COMPANY DATA
OFFICIAL DATA:
Legal form: Joint
stock company
Registration: 09-03-2005
First Publication: 30-03-2005
Last Publication: 22-12-2006
Share capital: 100.000
Paid up: 100.000
Divided into: 10.000
Bearer shares of 10
Direct Parent com.: Biosensors Interventional Technologies Pte Ltd, Singapour with a share of 100%.
Company Management: Jefrey B. Jump
Joo Chua Yang
ACTIVITY:
Activity:
This company is devoted to the
distribution of medical devices used in interventional cardiology in Europe, as
well as the provision of financial and trading services.
Biosensors Europe SA has a representative
office in Beijing/China.
EMPLOYEES:
Number of employees: 30
PAYMENT AND FINANCIAL DATA
PAYMENT EXPERIENCES:
Legal actions: Information only available
against proof of interest.
There are no recorded complaints on the
business conduct of the company and current liabilities are settled in an
orderly manner.
FINANCIAL DATA:
Financial position: The financial affairs are considered to be
in order.
Financial Statements: The company does not
disclose any financial statements.
Consolidated key figures (in MRO
1.000.000):
Biosensors Group
31.03.2006
31.03.2005
Sales 37'852.9
70'993.6
Operating Profit/Loss 21'088.6 59'745.7
Profit/Loss -22454.1
20'034.8
Cash-Flow 20'990.1
29'125.3
Banker(-s): UBS Ltd, 1110 Morges
Auditors: Ernst & Young SA, Lancy
Premises:
The premises at the above mentioned address are rented.
COMPANY AND PERSON
RELATIONS
COMPANY CONNECTIONS:
Direct Parent com.: Biosensors Interventional Technologies Pte
Ltd, Singapour with a share of 100%.
Ultimate Parent com.: Biosensors
International Group Ltd, Bermudes.
Biosensors International Group Ltd
develops, manufactures and commercializes innovative medical devices used in
interventional cardiology and critical care procedures.
Biosensors affiliated companies maintain offices in Newport Beach,
California, The netherlands, Germany, Switzerland, Singapore, and Japan. Their interventional products are currently
being manufactured in Singapore and The Netherlands.
Direct Investments:
Biosensors International (France) SARL,
Paris
(100.0%).
Biosensors International USA, Newport
Beach/Californie, America/US (100.0%).
Biosensors Japan Co., Ltd, Tokyo, Japan/JP
(100.0%).
BOARD OF DIRECTORS:
Yoh Chie Lu, from America, in
Newport/America,
President, collective signature.
Franz Nawratil, from Germany, in
Commugny/VD/Switzerland,
Secretary, collective signature.
Walter Carl G. Stresemann, from Fontenais,
in Le
Grand-Saconnex/GE/Switzerland,
Member, collective signature.
MANAGEMENT:
Yang Joo Chua, from Singapore, in
Morges/VD/Switzerland,
Director, collective signature.
Jeffrey B. Jump, from America, in
Prangins/VD/Switzerland,
Director, collective signature.
Ian Mc Currach, from United Kingdom, in
Lasne/Belgium,
Director, collective signature.
Peter Van Staveren, from Netherlands, in
Helligom/Netherlands,
Director, collective signature.
PERSONNEL INFORMATION:
Yoh Chie LU is both the Chairman and Chief
Executive Officer (CEO) of biosensors. Mr Lu is responsible for the business
strategy and direction of the Company, the implementation of the Company's
corporate plans and
policies, and general management of the
Company's business.
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)